DT05 Rec'd PCT/PTO 19 JAN 2005.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

(Continuation-in-Part Appl. No.

> Application of PCT/JP2003/009348 filed July 23, 2003)

Applicant(s): Taishi YOSHIDA et al.

Filed CONCOMITANTLY HEREWITH

PREVENTIVE AGENTS FOR For

DIABETES MELLITUS

TC/A.U.

Examiner

Docket No. : 04818CIP/HG

Confirm. No.:

Customer No.: 01933

Express Mail Mailing Label No.: EV 584 632 351 US

Date of Deposit: January 19, 2005

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450,

Alexan@fia, VA 22313-1450

Laraine Dobies

In the event that this Paper is late filed, and the necessary petition for extension of time is not filed concurrently herewith, please consider this as a Petition for the requisite extension of time, and to the extent not tendered by check attached hereto, authorization to charge the extension fee, or any other fee required in connection with this Paper

to Account No. 06-1378.

INFORMATION DISCLOSURE STATEMENT FILED CONCOMITANT WITH NEW CIP APPLICATION

COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, VA 22313-1450

SIR:

The enclosed Forms PTO/SB/08A and PTO/SB/08B identify all of the references cited in the International Search Report of WO 2004/009118A1 which is the 18-month publication of Japanese Patent Application No. PCT/JP2003/009348 filed July 23, 2003, of which the present application is a Continuation-in-Part Application. Because priority is claimed under 35 USC 120, copies are not required.

It is requested that the publications be considered with respect to the patentability of the present invention and that an initialed copy of the enclosed Forms PTO/SB/08A and PTO/SB/08B be returned to applicants to indicate that such publications have been considered and made "of record."

Frishauf, Holtz, Goodman & Chick, P.C. 767 Third Ave., 25th Floor New York, NY 10017-2023 Tel. No. (212) 319-4900 Fax No.: (212) 319-5101

MJC/ld

Respectfully/submitted,

MARSHALIGO. CHIEK Reg. No. 26,853 Please type a plus sign (+) inside this box \rightarrow

Substitute for Form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT					٠,٠			10 th 10 th 20 th 2 th 2 th 2 th 2 th 2 th 2 th			
					Filing Date			Herewith			
					First Named Inventor			Taishi YOSHIDA			
					Group Art Unit			••••			
					Examiner Name			-			
Sheet	Sheet 1 of 2			2	Attorney Docket Number			04818CIP/HG			
	1-		<u></u>		S. PATI	ENT DOCUMENTS			·		
Exam. Inits*	Cite No¹	Docume	Document Number		Kind Code ²	Name of Patentee Applicant	or	Publication Date MM-DD-YYYY	Relevant Portion		
	-!-			FOR	EIGN PA	TENT DOCUMENTS					
Exam Inits	Cite No¹	Offc³	Document Number4		Kind Code⁵	Name of Patentee or Applicant		Publication Date MM-DD-YYYY	Relevant Portion	Т ⁶	
		WIPO WO 01/47935		A2	Metabasis Ther. Ontogen Corp.		07-05-2001 09-23-1999				
	WIPO		WO 99/47549					A1			
Exami Signa	ture					Date Considered			ine through	<u> </u>	

^{*} EXAMINER: Initial if document considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

DATE MAILED: January 19, 2005

¹ Unique citation designation number. ² See kinds of U.S. Patent Documents. ¹ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Place a check here if English translation is attached.

10/522401 DT05 Rec'd PCT/PTO 19 JAN 200

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box \rightarrow

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for Form 1449A/PTO					Application	on Number					
					Filing Date		Herewith				
INFORMAT STATEMEN					First Name	ed Inventor	Taishi YOSHIDA				
					Group Art	Unit					
					Examiner 1	Name					
Sheet	2		of 2		Attorney I	Docket Number	04818CIP/HG				
OTHER PRIOR ART - NON-PATENT LITERATURE DOCUMENTS											
Examiner Initials ¹											
		WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", J. Med. Chem., 29 August, 2002 (29.08.02); 45(18): 3865-77 WRIGHT, et al., "Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazo lines.", Bioorg. Med. Chem. Lett., 08 January 2001 (08.01.01); 11(1):17-21 KNOWLER, et al., "Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.", N. Engl. J. Med., 07 February 2002 (07.02.02); 346(6):393-403. (abstract) Medline (PubMed) [online], PMID 11832527 SARTOR, et al., Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation.", Diabetes, 1980 January; 29(1):41-9. (abstract) Medline (PubMed) [online], PMID 7380107 NOLAN, et al., "Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone.", N. Engl. J. Med., 03 November 1994 (03.11.94); 331(18):1188-93. (abstract) Medline (PubMed) [online], PMID 7935656 ANTONUCCI, et al., "Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.", Diabetes Care, 1997 February; 20(2):188-93. (abstract) Medline (PubMed) [online], PMID 9118772									
Examiner Signature						Date Considered					

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 Place a check here if English translation is attached.